The Salford Lung Study: a pioneering comparative effectiveness approach to COPD and asthma in clinical trials

References

• VargessonNThalidomide-induced teratogenesis: history and mechanismsBirth Defects Res C Embryo Today2015105214015626043938
   PubMed Web of Science ®Google Scholar
• FishmanAPAminorex to fen/phen: an epidemic foretoldCirculation19999911561619884392
   PubMed Web of Science ®Google Scholar
• VolmarKEHutchinsGMAortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agentsArch Pathol Lab Med2001125121555156111735689
   PubMed Web of Science ®Google Scholar
• KancherlaMKSaltiHIMulderinkTAParkerMBonowROMehlmanDJEchocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramineAm J Cardiol199984111335133810614800
   PubMed Web of Science ®Google Scholar
• GardinJMSchumacherDConstantineGDavisKDLeungCReidCLValvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramineJAMA2000283131703170910755496
   PubMed Web of Science ®Google Scholar
• SachdevMMillerWCRyanTJollisJGEffect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studiesAm Heart J200214461065107312486432
   PubMed Web of Science ®Google Scholar
• KramerMSLaneDAAminorex, dexfenfluramine, and primary pulmonary hypertensionJ Clin Epidemiol19985143613649539893
   PubMed Web of Science ®Google Scholar
• WalkerAMLanglebenDKorelitzJJTemporal trends and drug exposures in pulmonary hypertension: an American experienceAm Heart J2006152352152616923424
   PubMed Web of Science ®Google Scholar
• JohnstonJACluxtonRJJrHeatonPCGuoJJMoomawCJEckmanMHPredictors of warfarin use among Ohio medicaid patients with new-onset nonvalvular atrial fibrillationArch Intern Med2003163141705171012885686
   PubMedGoogle Scholar
• ConnollySJEzekowitzMDYusufSRE-LY Steering Committee and InvestigatorsDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med2009361121139115119717844
   PubMed Web of Science ®Google Scholar
• BakerWLCiosDASanderSDColemanCIMeta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United StatesJ Manag Care Pharm200915324425219326955
   PubMed Web of Science ®Google Scholar
• PlattABLocalioARBrensingerCMRisk factors for nonadherence to warfarin: results from the IN-RANGE studyPharmacoepidemiol Drug Saf200817985386018271059
   PubMed Web of Science ®Google Scholar
• KneelandPPFangMCCurrent issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolismPatient Prefer Adherence20104516020361065
   PubMed Web of Science ®Google Scholar
• SciurbaFRennardSIRationale for a redundant formulary. The Hawthorne effect and the art of medicineAm J Respir Crit Care Med2015191111224122526029836
   PubMed Web of Science ®Google Scholar
• HagelSReischkeJKesselmeierMQuantifying the hawthorne effect in hand hygiene compliance through comparing direct observation with automated hand hygiene monitoringInfect Control Hosp Epidemiol201536895796225903555
   PubMed Web of Science ®Google Scholar
• Dal-RéRCould phase 3 medicine trials be tagged as pragmatic? A case study: the Salford COPD trialJ Eval Clin Pract Epub201777
   Web of Science ®Google Scholar
• FlayBREfficacy and effectiveness trials (and other phases of research) in the development of health promotion programsPrev Med19861554514743534875
   PubMed Web of Science ®Google Scholar
• GartlehnerGHansenRANissmanDLohrKNCareyTSCriteria for Distinguishing Effectiveness From Efficacy Trials in Systematic ReviewsRockville, MDAgency for Healthcare Research and Quality (US)2006
   Google Scholar
• ToshGSoares-WeiserKAdamsCEPragmatic vs explanatory trials: the pragmascope tool to help measure differences in protocols of mental health randomized controlled trialsDialogues Clin Neurosci201113220921521842618
   PubMedGoogle Scholar
• MullinRCost to Develop New Pharmaceutical Drug Now Exceeds $25BScientific AmericanSpringer Nature2014
   Google Scholar
• YildirimOGottwaldMSchülerPMichelMCOpportunities and challenges for drug development: public-private partnerships, adaptive designs and big dataFront Pharmacol2016746127999543
   PubMed Web of Science ®Google Scholar
• YinGLamCKShiHBayesian randomized clinical trials: from fixed to adaptive designContemp Clin Trials201759778628455232
   PubMed Web of Science ®Google Scholar
• Bent-EnnakhilNCosteFXieLA real-world analysis of treatment patterns for cholinesterase inhibitors and memantine among newly-diagnosed Alzheimer’s disease patientsNeurol Ther20176113114428508250
   PubMed Web of Science ®Google Scholar
• FriedenTREvidence for health decision making – beyond randomized, controlled trialsN Engl J Med2017377546547528767357
   PubMed Web of Science ®Google Scholar
• NewJPBakerlyNDLeatherDWoodcockAObtaining real-world evidence: the Salford Lung StudyThorax201469121152115424603195
   PubMed Web of Science ®Google Scholar
• CollierSHarveyCBrewsterJMonitoring safety in a phase III real-world effectiveness trial: use of novel methodology in the Salford Lung StudyPharmacoepidemiol Drug Saf201726334435227804174
   PubMed Web of Science ®Google Scholar
• ElkheniniHFDavisKJSteinNDUsing an electronic medical record (EMR) to conduct clinical trials: Salford Lung Study feasibilityBMC Med Inform Decis Mak201515825880660
   PubMed Web of Science ®Google Scholar
• BakerlyNDWoodcockANewJPThe Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in chronic obstructive pulmonary diseaseRespir Res20151610126337978
   PubMed Web of Science ®Google Scholar
• SyedYYFluticasone furoate/vilanterol: a review of its use in patients with asthmaDrugs201575440741825648266
   PubMed Web of Science ®Google Scholar
• AlbertsonTEBullickSWSchivoMSutterMESpotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapyDrug Des Devel Ther20161040474060
   PubMed Web of Science ®Google Scholar
• AlbertsonTERichardsJRZekiAAThe combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experienceTher Adv Respir Dis2016101435626668137
   PubMed Web of Science ®Google Scholar
• TanLDChanALAlbertsonTENew combination treatments in the management of asthma: focus on fluticasone/vilanterolJ Asthma Allergy20147778324833910
   PubMedGoogle Scholar
• CalzettaLRinaldiBCazzolaMMateraMGPharmacodynamic and pharmacokinetic assessment of fluticasone furoate + vilanterol for the treatment of asthmaExpert Opin Drug Metab Toxicol201612781382227253498
   PubMed Web of Science ®Google Scholar
• DwanKMilanSJBaxLWaltersNPowellCVilanterol and fluticasone furoate for asthmaCochrane Database Syst Rev20169CD01075827582089
   PubMed Web of Science ®Google Scholar
• WoodcockABakerlyNDNewJPThe Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in asthmaBMC Pulm Med20151516026651333
   PubMed Web of Science ®Google Scholar
• VestboJLeatherDDiar BakerlyNSalford Lung Study InvestigatorsEffectiveness of fluticasone furoate-vilanterol for COPD in clinical practiceN Engl J Med2016375131253126027593504
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.govA randomised effectiveness study comparing fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) with standard treatment in chronic obstructive pulmonary disease (COPD)2017 Available from: https://clinicaltrials.gov/ct2/show/NCT01551758Accessed July 27, 2017
   Google Scholar
• McKeageKFluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary diseaseDrugs201474131509152225074268
   PubMed Web of Science ®Google Scholar
• MartinezFJVestboJAndersonJASUMMIT InvestigatorsEffect of fluticasone furoate and vilanterol on exacerbations of chronic obstructive pulmonary disease in patients with moderate airflow obstructionAm J Respir Crit Care Med2017195788188827767328
   PubMed Web of Science ®Google Scholar
• KardosPWorsleySSinghDRomán-RodríguezMNewbyDEMüllerováHRandomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPDInt J Chron Obstruct Pulmon Dis2016112885289527932872
   PubMedGoogle Scholar
• SchivoMAlbertsonTEHaczkuAParadigms in chronic obstructive pulmonary disease: phenotypes, immunobiology, and therapy with a focus on vascular diseaseJ Investig Med2017656953963
   Web of Science ®Google Scholar
• NanniniLJPoolePMilanSJHolmesRNormansellRCombined corticosteroid and long-acting beta2-agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseCochrane Database Syst Rev201311CD00379424214176
   PubMed Web of Science ®Google Scholar
• KewKMDiasSCatesCJLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisCochrane Database Syst Rev20143CD01084424671923
   PubMed Web of Science ®Google Scholar
• MateraMGCapuanoACazzolaMFluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary diseaseExpert Rev Respir Med20159151225482512
   PubMed Web of Science ®Google Scholar
• BatemanEDMahlerDAVogelmeierCFWedzichaJAPatalanoFBanerjiDRecent advances in COPD disease management with fixed-dose long-acting combination therapiesExpert Rev Respir Med20148335737924802656
   PubMed Web of Science ®Google Scholar
• VestboJAndersonJABrookRDSUMMIT InvestigatorsFluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trialLancet2016387100301817182627203508
   PubMed Web of Science ®Google Scholar
• KewKMSeniukovichAInhaled steroids and risk of pneumonia for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20143CD01011524615270
   PubMed Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRFLAME InvestigatorsIndacaterol-glycopyrronium versus salmeterol-fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• ZhongNWangCZhouXLANTERN InvestigatorsLANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPDInt J Chron Obstruct Pulmon Dis2015101015102626082625
   PubMed Web of Science ®Google Scholar
• LalCStrangeCSpotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapyInt J Chron Obstruct Pulmon Dis201612135140 eCollection 201728115838
   PubMed Web of Science ®Google Scholar
• BarnishMSTurnerSThe value of pragmatic and observational studies in health care and public healthPragmat Obs Res20178495528546780
   PubMed Web of Science ®Google Scholar